Bangladesh - English - DGDA (Directorate General of Drug Administration)

ambee pharmaceuticals ltd. - omeprazole - capsule - 20 mg

Bangladesh - English - DGDA (Directorate General of Drug Administration)

ambee pharmaceuticals ltd. - omeprazole - capsule - 40 mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

vifor pharma uk ltd - patiromer sorbitex calcium - powder - 16.8gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

vifor pharma uk ltd - patiromer sorbitex calcium - powder - 8.4gram

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

om pharma s.a., portugal - patiromer sorbitex calcium - powder for oral suspension - 25.2 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

om pharma s.a., portugal - patiromer sorbitex calcium - powder for oral suspension - 16.8 g

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

om pharma s.a., portugal - patiromer sorbitex calcium - powder for oral suspension - 8.4 g

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - oxazepam, quantity: 30 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; quinoline yellow aluminium lake; maize starch; erythrosine aluminium lake - indications as at 25 january 2005 : alepam is indicated for: management of anxiety disorders or for the short-term relief of the symptoms of anxiety. anxiety associated with depression is also responsive to oxazepam therapy. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the physician should periodically reassess the usefulness of the drug for the individual patient. alcoholics with acute tremulousness, confusional state or anxiety associated with alcohol withdrawal are responsive to therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - oxazepam, quantity: 15 mg - tablet, uncoated - excipient ingredients: magnesium stearate; erythrosine aluminium lake; maize starch; quinoline yellow aluminium lake; lactose monohydrate - indications as at 25 january 2005 : alepam is indicated for: management of anxiety disorders or for the short-term relief of the symptoms of anxiety. anxiety associated with depression is also responsive to oxazepam therapy. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the physician should periodically reassess the usefulness of the drug for the individual patient. alcoholics with acute tremulousness, confusional state or anxiety associated with alcohol withdrawal are responsive to therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - buprenorphine hydrochloride 2.16mg equivalent to 2 mg buprenorphine; naloxone hydrochloride dihydrate 0.61mg equivalent to 0.5 mg naloxone - sublingual tablet - 2mg/0.5mg - active: buprenorphine hydrochloride 2.16mg equivalent to 2 mg buprenorphine naloxone hydrochloride dihydrate 0.61mg equivalent to 0.5 mg naloxone excipient: acesulfame potassium citric acid lactose monohydrate lemon flavour phs-020484 magnesium stearate maize starch mannitol povidone sodium citrate dihydrate - treatment of opiate dependence, within a framework of medical, social and psychological treatment. naloxone is included in suboxone to deter intravenous misuse of the product.